Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma
Authors
Keywords
-
Journal
Liver Cancer
Volume 11, Issue 1, Pages 38-47
Publisher
S. Karger AG
Online
2021-12-04
DOI
10.1159/000519867
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
- (2020) Robin Kate Kelley et al. CLINICAL CANCER RESEARCH
- Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design
- (2020) Robin Kate Kelley et al. Future Oncology
- Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
- (2019) Michael Teufel et al. GASTROENTEROLOGY
- Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
- (2019) David J. Pinato et al. BRITISH JOURNAL OF CANCER
- Circulating tumor cells undergoing EMT are poorly correlated with clinical stages or predictive of recurrence in hepatocellular carcinoma
- (2019) Yunyang Chen et al. Scientific Reports
- The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma
- (2019) Chandan Sanghera et al. LIVER INTERNATIONAL
- Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
- (2018) Ian Chau et al. BRITISH JOURNAL OF CANCER
- A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types
- (2018) Steven Lacy et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
- (2018) Lorenza Rimassa et al. LANCET ONCOLOGY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
- (2017) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients
- (2017) Jack P. Silva et al. JOURNAL OF SURGICAL ONCOLOGY
- The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma
- (2017) Dou-Sheng Bai et al. Scientific Reports
- Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial
- (2016) Raya Leibowitz-Amit et al. Journal of Translational Medicine
- Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma
- (2016) Stephen L. Chan et al. LIVER INTERNATIONAL
- Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients
- (2016) Sara M. Tolaney et al. ONCOLOGIST
- Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor–Targeted Therapy for Renal Cell Carcinoma
- (2016) Andrew G. Winer et al. UROLOGIC CLINICS OF NORTH AMERICA
- Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
- (2016) Lorenza Rimassa et al. Oncotarget
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
- (2015) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
- (2015) L Zhou et al. ONCOGENE
- Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?
- (2015) Yu-Yun Shao WORLD JOURNAL OF GASTROENTEROLOGY
- Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy
- (2012) Y.-Y. Shao et al. CLINICAL CANCER RESEARCH
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
- (2012) Nicola Personeni et al. JOURNAL OF HEPATOLOGY
- Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer
- (2011) Takeshi Yuasa et al. CANCER SCIENCE
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
- (2011) T. Yau et al. ONCOLOGIST
- Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
- (2010) Yu-Yun Shao et al. CANCER
- Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
- (2009) N Murukesh et al. BRITISH JOURNAL OF CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy
- (2008) Stephen L. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started